Cargando…
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increased pulmonary artery pressure leading to right ventricular (RV) failure. While current PAH therapies improve patient outlook, they show limited benefit in attenuating RV dysfunction. Recent investigatio...
Autores principales: | Mulvaney, Eamon P., Renzo, Fabiana, Adão, Rui, Dupre, Emilie, Bialesova, Lucia, Salvatore, Viviana, Reid, Helen M., Conceição, Glória, Grynblat, Julien, Llucià-Valldeperas, Aida, Michel, Jean-Baptiste, Brás-Silva, Carmen, Laurent, Charles E., Howard, Luke S., Montani, David, Humbert, Marc, Vonk Noordegraaf, Anton, Perros, Frédéric, Mendes-Ferreira, Pedro, Kinsella, B. Therese |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794752/ https://www.ncbi.nlm.nih.gov/pubmed/36588576 http://dx.doi.org/10.3389/fcvm.2022.1063967 |
Ejemplares similares
-
NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension
por: Mulvaney, Eamon P., et al.
Publicado: (2020) -
Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer
por: O'Sullivan, Aine G., et al.
Publicado: (2015) -
Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential
por: Mulvaney, Eamon P., et al.
Publicado: (2016) -
NTP Update
Publicado: (1995) -
An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
por: Santos-Gomes, Joana, et al.
Publicado: (2022)